Speaker
Spencer Liberman
Appearances over time
1 episodes
Episodes
1
Podcasts
Quotes & moments
CRH agreed to acquire US construction services company Arcosa for $8.5 billion, the largest deal in CRH's history.
Following the Arcosa deal, CRH becomes the largest US aggregates producer at approximately 265 million tons per year.
CRH made approximately 38 acquisitions in the prior year, totaling about $4 billion, mostly bolt-on deals before the record Arcosa transaction.
CRH is currently working on over 100 data center projects, representing a growing high-demand growth avenue.
Chevron is turning stranded Permian Basin natural gas — so abundant it overwhelms pipelines and must be burned as waste — into a 2.67-gigawatt power plant for Microsoft's AI data center. The project is 100% behind the meter, no utility involved, no impact on local ratepayers.
Early on, big tech preferred renewables for data centers and building near population centers. But the sheer scale of AI compute demand is forcing a pragmatic turn to natural gas — and remote locations with cheap, abundant energy are now competitive advantages.
AbbVie already has the biggest immunology franchise in pharma with Skyrizi and Rinvoq heading toward $50B+ in combined revenue. Buying Apogee for $10.9 billion gives it a foothold in atopic dermatitis — a massive and underserved eczema market.
The entire pharma world is chasing obesity drugs worth $100 billion. But AbbVie's two immunology drugs — Skyrizi and Rinvoq — are already approaching $50 billion combined. Inflammation is a pharma goldmine that doesn't get nearly enough attention.
Big pharma runs at 30%+ operating margins across the board. Even Pfizer, whose stock has halved from pandemic peaks, generates enormous cash with low leverage. These are cash-rich companies, and large all-cash acquisitions are entirely within reach for almost all of them.
Immunology is well-mapped. Obesity is crowded. The next great pharmaceutical frontier is neuroscience — the brain remains largely a black box, but new biology is unlocking it fast. That's where the next wave of breakthrough drugs will come from.
Women's health has historically received far less pharmaceutical attention than it deserves. The FDA's removal of the black box warning on hormone replacement therapy is now unlocking new commercial interest — and changing how the industry thinks about estrogen-based treatments.
CRH just did something it has never done before: a single deal bigger than $4 billion. The $8.5 billion Arcosa acquisition makes CRH the largest US aggregates producer at 265 million tons per year, and positions it as the vertically integrated one-stop shop for US construction.
Aggregates — the crushed stone, sand, and gravel used in roads and concrete — maintain pricing power even when cement and asphalt decline. In down cycles, aggregates still grow prices. That's the rarest quality in building materials and why CRH is doubling down.
Greenspan presided over 15 years of the Great Moderation — and it may have been his undoing. Hyman Minsky's paradox: long periods of stability breed the overconfidence that causes instability. Greenspan's light regulatory touch and deep belief in markets left him blind to the real estate crisis forming in his final years.
Kevin Warsh pulled off a difficult balancing act in his first FOMC meeting: launching 5 reform task forces while reaffirming the committee's inflation-fighting commitment. His decision not to submit a personal forecast or dot was a quiet signal — and the SEP was the most hawkish document in the room.
Oil prices have come down recently, and some see an inflation problem solving itself. But Dennis Lockhart warns against assuming pre-war price levels return. Inflationary pressures could persist — and any improvement could reverse quickly depending on geopolitical negotiations.
Analysis
What they talk about
- Business 100%
Connections
Shows they appear on and people they share episodes with. Drag to explore.
